- Home
- SUPV vs FULC Comparison
SUPV vs FULC Comparison
Compare SUPV & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | FULC |
|---|---|---|
| Founded | 1887 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 718.4M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SUPV | FULC |
|---|---|---|
| Price | $8.37 | $7.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $13.00 | ★ $16.38 |
| AVG Volume (30 Days) | 1.0M | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.63 | N/A |
| Revenue Next Year | $43.89 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $2.32 |
| 52 Week High | $17.02 | $15.74 |
Technical Indicators
Market Signals| Indicator | SUPV | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 33.46 |
| Support Level | $4.71 | $7.40 |
| Resistance Level | $11.76 | $8.50 |
| Average True Range (ATR) | 0.62 | 0.79 |
| MACD | -0.19 | -0.18 |
| Stochastic Oscillator | 16.02 | 4.66 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.